Myeloma: Update on Supportive Care Strategies

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2003 Apr 30

PMID 12718802

Authors

Jesus F San Miguel

Ramon Garcia-Sanz

Affiliations

Soon will be listed here.

Abstract

Despite substantial innovations in the treatment of multiple myeloma (MM), it remains an incurable disease. In addition, it is debatable whether the progress in survival is attributable simply to the therapy used to destroy the tumor clone or if it is also because of therapy designed to ameliorate disease complications. Supportive therapy has evolved greatly alongside general supportive measures used in hematologic malignancies (such as new antibiotics, antifungal agents, and growth factors) in addition to better indications in complementary treatments such as radiotherapy, dialysis, and surgery. However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM.

References

Nussbaum S, Warrell Jr R, Rude R, Glusman J, Bilezikian J, Stewart A . Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol. 1993; 11(8):1618-23. DOI: 10.1200/JCO.1993.11.8.1618. View

Martin A, Garcia-Sanz R, Hernandez J, Blade J, Suquia B, Fernandez-Calvo J . Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol. 2002; 118(1):239-42. DOI: 10.1046/j.1365-2141.2002.03549.x. View

Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N . Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A. 2001; 98(9):5181-6. PMC: 33184. DOI: 10.1073/pnas.081275298. View

Ljungman P . Immunization of transplant recipients. Bone Marrow Transplant. 1999; 23(7):635-6. DOI: 10.1038/sj.bmt.1701641. View

Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R, Navari R . Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994; 154(17):1935-44. DOI: 10.1001/archinte.154.17.1935. View

Chapel H, Lee M, Hargreaves R, Pamphilon D, Prentice A . Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994; 343(8905):1059-63. DOI: 10.1016/s0140-6736(94)90180-5. View

LEVINE S, Perin L, Hayes D, Hayes W . An evidence-based evaluation of percutaneous vertebroplasty. Manag Care. 2000; 9(3):56-60, 63. View

Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, ESSERS U . Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995; 86(12):4446-53. View

San Miguel J, Blade Creixenti J, Garcia-Sanz R . Treatment of multiple myeloma. Haematologica. 1999; 84(1):36-58. View

10.

Lahtinen R, Laakso M, PALVA I, Virkkunen P, Elomaa I . Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992; 340(8827):1049-52. DOI: 10.1016/0140-6736(92)93075-x. View

11.

Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C . Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol. 2002; 119(1):79-86. DOI: 10.1046/j.1365-2141.2002.03774.x. View

12.

Daragon A, Humez C, Michot C, Le Loet X, Grosbois B, Pouyol F . Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM). Eur J Med. 1993; 2(8):449-52. View

13.

San Miguel J, Lahuerta J, Garcia-Sanz R, Alegre A, Blade J, Martinez R . Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. Hematol J. 2002; 1(1):28-36. DOI: 10.1038/sj.thj.6200003. View

14.

Rizzo J, Lichtin A, Woolf S, Seidenfeld J, Bennett C, Cella D . Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002; 100(7):2303-20. DOI: 10.1182/blood-2002-06-1767. View

15.

Purohit O, Radstone C, Anthony C, Kanis J, Coleman R . A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer. 1995; 72(5):1289-93. PMC: 2033943. DOI: 10.1038/bjc.1995.502. View

16.

Fassas A, Bolanos-Meade J, Buddharaju L, Rapoport A, Cottler-Fox M, Chen T . Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol. 2001; 112(1):237-41. DOI: 10.1046/j.1365-2141.2001.02487.x. View

17.

Tricot G, Alberts D, JOHNSON C, Roe D, Dorr R, Bracy D . Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996; 2(6):947-52. View

18.

Dudeney S, Lieberman I, Hussein M . Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol. 2002; 20(9):2382-7. DOI: 10.1200/JCO.2002.09.097. View

19.

Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens X, Montoto S . Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158(17):1889-93. DOI: 10.1001/archinte.158.17.1889. View

20.

Osterborg A, Boogaerts M, Cimino R, ESSERS U, Holowiecki J, Juliusson G . Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and.... Blood. 1996; 87(7):2675-82. View